Study of p73 Protein in Liver Cancer
Author Information
Author(s): Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mössner J, Wittekind Ch
Primary Institution: Institute of Pathology, University of Leipzig
Hypothesis
The study aims to investigate the expression of p53, its homologue p73, and the occurrence of apoptosis in cholangiocellular carcinoma.
Conclusion
The study found that while p73 is prevalent in tumors with mutated p53, neither p73 nor p53 were established as independent prognostic factors.
Supporting Evidence
- Immunostaining of p73 protein was detected in 17 out of 41 carcinomas examined.
- In 15 out of 41 patients, mutations of the p53 gene were observed.
- Out of 26 patients without detectable p53 mutation, only six exhibited p73 immunostaining.
- Survival analysis showed that tumor stage and grade were significantly related to prognosis.
Takeaway
Researchers looked at a protein called p73 in liver cancer and found it often appears when another protein, p53, is mutated, but it doesn't help predict how well someone will do.
Methodology
Protein levels of p73 were examined using an antiserum in 41 patients, and mutations in the p53 gene were analyzed by sequencing and immunohistochemistry.
Limitations
The study did not establish p73 or p53 as independent prognostic factors.
Participant Demographics
Patients with curatively resected cholangiocellular carcinomas.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website